Clinical Trials

Doctor smiling with patient

Our approach to clinical trials

Sangamo is conducting several clinical trials to evaluate the safety, tolerability, and potential efficacy of its genomic medicines, some of which we lead and some of which are led by our global pharmaceutical company collaboration partners.

Medical advances depend on the participation of patients in clinical studies. We are grateful to all participants in our clinical trials, their friends and families, who make a positive contribution towards a better future for all people living with severe diseases.

Learn more about our currently recruiting clinical trials below.


Currently Recruiting Patients

Ongoing Studies (Not Currently Recruiting)

  • Beta Thalassemia
    • Candidate ST-400
    • Study Thales Study
    • A Phase 1/2 clinical trial evaluating the safety, tolerability, and efficacy of ST-400 ex vivo cell therapy in transfusion-dependent beta thalassemia is ongoing and no longer recruiting.

      Learn More
  • Hemophilia A
    • Candidate SB-525/giroctocogene fitelparvovec
    • Study Alta Study
    • A Phase 1/2 clinical trial evaluating the safety, tolerability, and time-course profile of FVIII activity levels of SB-525/giroctocogene fitelparvovec gene therapy in hemophilia A is ongoing and no longer recruiting.

      Learn More

Resources